Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-31

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CT imaging data from lung cancer (NSCLC and SCLC) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.

NCT05046366

Artificial Intelligence Deep Learning Pathology, Molecular +5 more

UNKNOWN

Imaging-based Deep Learning for Lung Cancer Diagnosis and Staging

NCT04000620

Lung Cancer

UNKNOWN

Lung Nodule Imaging Biobank for Radiomics and AI Research

NCT04270799

Lung Cancer Pulmonary Nodule, Multiple Pulmonary Nodule, Solitary +1 more

UNKNOWN

AI Models for Predicting Occult Pleural Dissemination in NSCLC

NCT07065422

Non-Small Cell Lung Cancer

COMPLETED

Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

NCT05925751

Non-small Cell Lung Cancer Neoadjuvant Chemoimmunotherapy Complete Pathological Response

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer (Diagnosis)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients were treated for lung cancer in Wuhan Union Hospital from July 2025 to July 2026;
2. Aged \> 18 years old;
3. At least one CT scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion Criteria

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than lung cancer;
4. Unclear pathological diagnosis.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No